Evidence map›Paper›PMID 25849461›Full record

ArticlePloS one2015

Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients.

Motomu Hashimoto, Toru Yamazaki, Masahide Hamaguchi, Takeshi Morimoto, Masashi Yamori, Keita Asai, Yu Isobe, Moritoshi Furu, Hiromu Ito, Takao Fujii and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Canine Pyometra: A Short Review of Current Advances.Animals : an open access journal from MDPI · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Motomu HashimotoDepartment of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Toru YamazakiDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahide HamaguchiDepartment of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takeshi MorimotoDivision of General Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Masashi YamoriDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keita AsaiDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yu IsobeDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Moritoshi FuruDepartment of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiromu ItoDepartment of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takao FujiiDepartment of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Chikashi TeraoCenter for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masato MoriDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takashi MatsuoDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroyuki YoshitomiCenter for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keiichi YamamotoDepartment of Clinical Epidemiology and Biostatistics, Graduate School of Medicine, Osaka University, Osaka, Japan.
Wataru YamamotoDepartment of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan.
Kazuhisa BesshoDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tsuneyo MimoriDepartment of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPHyogo Medical University · JPKurashiki Central Hospital · JPKyoto Prefectural University of Medicine · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine whether the presence of periodontitis (PD) and Porphyromonas gingivalis (Pg) in the subgingival biofilm associates with the development of rheumatoid arthritis (RA) in treatment naïve preclinical stage of arthritis patients.

methodsWe conducted a prospective cohort study of 72 consecutive patients with arthralgia who had never been treated with any anti-rheumatic drugs or glucocorticoids. Periodontal status at baseline was assessed by dentists. PD was defined stringently by the maximal probing depth≧4 mm, or by the classification by the 5th European Workshop in Periodontology (EWP) in 2005 using attachment loss. Up to eight plaque samples were obtained from each patient and the presence of Pg was determined by Taqman PCR. The patients were followed up for 2 years and introduction rate of methotrexate (MTX) treatment on the diagnosis of RA was compared in patients with or without PD or Pg.

resultsPatients with PD (probing depth≧4mm) had higher arthritis activity (p = 0.02) and higher risk for future introduction of MTX treatment on the diagnosis of RA during the follow up than patients without PD (Hazard ratio 2.68, p = 0.03). Arthritis activity and risk for MTX introduction increased with the severity of PD assessed by EWP, although not statistically significant. On the other hand, presence of Pg was not associated with arthritis activity (p = 0.72) or the risk for MTX introduction (p = 0.45).

conclusionIn treatment naïve arthralgia patients, PD, but not the presence of Pg, associates with arthritis activity and future requirement of MTX treatment on the diagnosis of RA.

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidBiofilmsCohort StudiesFemaleHumansMaleMethotrexateMiddle AgedMultivariate AnalysisPeriodontitisPorphyromonas gingivalisProportional Hazards ModelsProspective StudiesAntirheumatic AgentsMethotrexate

Identifiers

PMID25849461
PMCPMC4388350
OpenAlexW2017974217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.